Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goldhirsch

Showing results (511-520 of 753) with videos related to

Pageof 76
Sort By:
Breast Cancer Research and Treatment|March 13, 2009
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyEugenio Maiorano, Meredith M Regan, Giuseppe Viale, et al.
British Journal of Cancer|May 29, 2008
Factors that predict early treatment failure for patients with locally advanced (T4) breast cancerE Montagna, V Bagnardi, N Rotmensz, et al.
Anti-Cancer Drugs|February 3, 2009
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic featuresAlessandra Balduzzi, Emilia Montagna, Vincenzo Bagnardi, et al.
Breast (Edinburgh, Scotland)|March 15, 2011
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancerSilvia Dellapasqua, Manuelita Mazza, Debora Rosa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)M M Borner, M Castiglione, M Bacchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to VMarco Colleoni, Zhuoxin Sun, Karen N Price, et al.
Breast (Edinburgh, Scotland)|August 16, 2006
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancerRosalba Torrisi, Marco Colleoni, Paolo Veronesi, et al.
British Journal of Cancer|August 23, 2007
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancerR Torrisi, V Bagnardi, G Pruneri, et al.
Clinical Breast Cancer|November 5, 2013
Outcomes of patients with breast cancer who present with ipsilateral supraclavicular or internal mammary lymph node metastasesSilvia Dellapasqua, Vincenzo Bagnardi, Alessandra Balduzzi, et al.
Cancer Letters|January 30, 2017
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trialEmilia Montagna, Antonella Palazzo, Patrick Maisonneuve, et al.
Pageof 76

Showing results (511-520 of 753) with videos related to

Sort By:
Pageof 76
Breast Cancer Research and Treatment|March 13, 2009
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyEugenio Maiorano, Meredith M Regan, Giuseppe Viale, et al.
British Journal of Cancer|May 29, 2008
Factors that predict early treatment failure for patients with locally advanced (T4) breast cancerE Montagna, V Bagnardi, N Rotmensz, et al.
Anti-Cancer Drugs|February 3, 2009
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic featuresAlessandra Balduzzi, Emilia Montagna, Vincenzo Bagnardi, et al.
Breast (Edinburgh, Scotland)|March 15, 2011
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancerSilvia Dellapasqua, Manuelita Mazza, Debora Rosa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)M M Borner, M Castiglione, M Bacchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to VMarco Colleoni, Zhuoxin Sun, Karen N Price, et al.
Breast (Edinburgh, Scotland)|August 16, 2006
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancerRosalba Torrisi, Marco Colleoni, Paolo Veronesi, et al.
British Journal of Cancer|August 23, 2007
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancerR Torrisi, V Bagnardi, G Pruneri, et al.
Clinical Breast Cancer|November 5, 2013
Outcomes of patients with breast cancer who present with ipsilateral supraclavicular or internal mammary lymph node metastasesSilvia Dellapasqua, Vincenzo Bagnardi, Alessandra Balduzzi, et al.
Cancer Letters|January 30, 2017
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trialEmilia Montagna, Antonella Palazzo, Patrick Maisonneuve, et al.
Pageof 76